Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102

Hamauchi, Satoshi; Yamazaki, Kentaro; Masuishi, Toshiki; Kito, Yosuke; Komori, Azusa; Tsushima, Takahiro; Narita, Yuji; Todaka, Akiko; Ishihara, Makoto; Yokota, Tomoya; Tanaka, Tsutomu; Machida, Nozomu; Kadowaki, Shigenori; Fukutomi, Akira; Umemura, Takashi; Onozawa, Yusuke; Ando, Masashi; Tajika, Masahiro; Muro, Kei; Yasui, Hirofumi; Mori, Keita; Taniguchi, Hiroya

doi:10.1016/j.clcc.2016.07.005

Cited by 53 publications

(51 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, the treatment was manageable, requiring permanent discontinuation because of adverse events only in a limited percentage of cases (3%). A significant association of grade 3 neutropenia with PFS and OS was reported at the univariate analyses and confirmed after adjusting for the number of cycles received, thus supporting the potential meaning of neutropenia as a surrogate marker for adequate antitumor doses of TAS-102, as previously hypothesized [18].…”

Section: Discussionsupporting

confidence: 79%

Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program

et al. 2018

View full text Add to dashboard Cite

Improving the cost-efficacy ratio of TAS-102 in metastatic colorectal cancer is needed to spare useless toxicities in a definitely palliative setting. Eastern Cooperative Oncology Group performance status, lactate dehydrogenase levels, and time from the diagnosis of metastatic disease may help to identify patients more likely to achieve benefit. Properly designed prognostic tools (i.e., the "ColonLife" nomogram) may enable excluding from further treatments patients with very limited life expectancy.

show abstract

Section: Discussionsupporting

confidence: 79%

Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program

et al. 2018

View full text Add to dashboard Cite

show abstract

“…This adverse event was associated with better treatment outcomes (mPFS of 7 months and increased mOS). Previously reported data demonstrated that, in patients with advanced colorectal cancer, FTD/TPI-induced severe neutropenia was associated with superior survival (2,(6)(7)(8). The reported frequency of grade 3-4 neutropenia in FTD/TPI users is 31-50% (2,7-9).…”

Section: Discussionmentioning

confidence: 99%

Duration of previous treatment as a prognostic factor in metastatic colorectal cancer treated with trifluridine/tipiracil

et al. 2018

View full text Add to dashboard Cite

Abstract. We herein describe the findings from the trifluridine/tipiracil (TAS-102) Compassionate Use program in Latvia, set up prior to marketing authorization for the management of pretreated patients with metastatic colorectal cancer (mCRC). The efficacy and safety of TAS-102 in patients with refractory mCRC were evaluated in the phase III trial RECOURSE. A previous report confirmed neutropenia and duration of previous treatment for mCRC as prognostic factors in TAS-102 users. The aim of the present study was to analyze possible prognostic factors, such as neutropenia, in TAS-102 responders. A retrospective analysis of 14 patients who received TAS-102 chemotherapy in two institutions in Latvia

show abstract

“…In another study, grade 3 or 4 CIN-1-month was shown to be associated with longer PFS than grade 0-2 CIN-1-month (4.3 vs. 2.0 months). Moreover, G3 or G4 neutropenia during the first cycle of TAS-102 therapy turned out to be associated with significantly higher DCR (72.2%) than grade 0-2 neutropenia (72.2 vs. 30.9%) [36]. Finally, a significant association was found between baseline creatinine clearance rate of less than 57.1 mL/min prior to TAS-102 administration and the incidence of G3 or G4 neutropenia after introduction of this agent [37].…”

Section: Predictorsmentioning

confidence: 93%

Further Therapeutic Options in Heavily Pretreated Colorectal Cancer Patients

Zygulska¹

2019

Multidisciplinary Approach for Colorectal Cancer

View full text Add to dashboard Cite

In this paper, currently available systemic treatment options (regorafenib, trifluridine/tipiracil, re-challenge chemotherapy, mitomycin C plus capecitabine) for pretreated patients with metastatic colorectal cancer are discussed and compared in terms of their efficacy and safety profiles. Treatment of these patients has remained a challenge for oncologists. The evidence from clinical trials is encouraging. Knowledge of response biomarkers and/or prognostic factors may be helpful in the identification of patients who could benefit most from the treatment. Adequate medication compliance can be achieved due to awareness of toxicity risk among both physicians and cancer patients and appropriate prevention and management of adverse events.

show abstract

Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102

Cited by 53 publications

References 19 publications

Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program

Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program

Duration of previous treatment as a prognostic factor in metastatic colorectal cancer treated with trifluridine/tipiracil

Further Therapeutic Options in Heavily Pretreated Colorectal Cancer Patients

Contact Info

Product

Resources

About